US Sex Cord Gonadal Stromal Tumor Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

US Sex Cord Gonadal Stromal Tumor Market Trends and Insights

Rising FDA-Backed Treatment Access for Rare Ovarian Sex Cord-Stromal Tumors

The FDA approved Verastem's Avmapki Fakzynja Co-Pack in May 2025, combining avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. This approval highlights the potential of precision oncology and sets a precedent for hormone-sensitive ovarian tumor treatments. It demonstrates that niche, molecularly defined segments can achieve regulatory approval and secure 7-year Orphan Drug exclusivity. The FDA's Real-Time Oncology Review is encouraging biomarker-driven strategies like FOXL2, DICER1, and NOTCH1 in the United States sex cord gonadal stromal tumor market, where competition remains limited.

Expanding Biomarker-Driven Patient Identification

Biomarker testing is broadening the patient base in the United States sex cord gonadal stromal tumor market. Institutions like UCSF Health and Mayo Clinic Laboratories now offer FOXL2 C402G testing through standardized workflows, enabling faster treatment planning and reliable monitoring. A 2025 study showed FOXL2-mutant circulating tumor DNA predicts post-operative disease progression in adult granulosa cell tumors. Another study highlighted that DICER1-mutant Sertoli-Leydig cell tumors have higher proliferative activity and worse prognosis, emphasizing the importance of genotyping at diagnosis. These advancements enhance diagnostic accuracy and create recurring revenue streams.

Growing Clinical Use of Surgery Plus Systemic Therapy

Treatment approaches in the United States sex cord gonadal stromal tumor market are evolving, with systemic therapy complementing surgery in advanced cases. A 2024 study confirmed paclitaxel-carboplatin and BEP as effective options, reinforcing multi-cycle systemic treatments in care. Each additional cycle increases treatment intensity and revenue.^{[2]Clinical Trial Record, “Phase II Study of Nirogacestat in Patients With Relapsed Ovarian Granulosa Cell Tumours,” PubMed, pubmed.ncbi.nlm.nih.gov} Interest is growing in CDK4/6 inhibitors with endocrine therapy for recurrent adult granulosa cell tumors, with a 2025 report showing 27.3% partial response and 54.5% stable disease. Emerging regimens like palbociclib with estrogen blockade are also gaining traction.

Increasing Trial Activity in Low-Grade Serous and Granulosa Cell Tumors

Clinical trials are driving growth in the United States sex cord gonadal stromal tumor market. NRG-GY033, launched in January 2024, evaluates darolutamide, leuprolide acetate, and exemestane for recurrent adult-type ovarian granulosa cell tumors. Trial participation increases spending through specialist visits, imaging, and monitoring. SpringWorks Therapeutics' Phase 2 nirogacestat study enrolled 53 patients in under a year, with the NOTCH1-mutant subgroup achieving 100% 6-month progression-free survival. Basket-trial approaches are reducing development barriers by integrating SCGST cohorts into broader rare tumor programs.

Very Small Eligible Patient Pool and Late Recurrence Patterns

The United States market for sex cord gonadal stromal tumors faces constraints due to a small patient base, with only 1,500-2,000 new cases annually. Adult granulosa cell tumors add complexity as recurrences often occur years after diagnosis, spreading demand over an extended timeline. A 2024 study in the Journal of Ovarian Research reported recurrence rates of 6-48%, with 50-80% of fatal cases occurring after relapse. Treatment intensity is concentrated on a small recurrent subset, limiting market growth more by disease epidemiology than treatment adoption.

High Dependence on Expert Pathology and Molecular Confirmation

Accurate diagnosis in the United States sex cord gonadal stromal tumor market depends on expert pathology and molecular testing. FOXL2 analysis requires specific tumor content and sequencing quality, posing challenges for smaller centers with limited experience. Community hospitals face misclassification risks without specialist reviews, especially outside major academic hubs where access to gynecologic oncology expertise and advanced sequencing is limited. Delayed confirmation slows treatment initiation and reduces patient referrals, though broader networks and accessible testing may gradually address this issue.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Tumor Type: Adult-Type Tumors Anchor Revenue While Juvenile and Rare Subtypes Gain Momentum

In 2025, adult granulosa cell tumors accounted for 59.6% of the United States sex cord gonadal stromal tumor market. Juvenile granulosa cell tumors are projected to grow at a 9.88% CAGR through 2031. Adult-type tumors dominate revenue due to their clinical prevalence and long-term recurrence, which drives extended surveillance and treatment. CDK4/6 inhibitor combinations are gaining traction as a later-line option for recurrent adult granulosa cell tumors, with studies showing partial response rates of 27.3% and stable disease rates of 54.5%. Juvenile granulosa cell tumors are expanding faster due to increased DICER1-focused pediatric programs, while Sertoli-Leydig cell tumors are becoming diagnostically significant with TERT and TP53 mutations indicating a less favorable prognosis. Thecomas, fibroma/fibrothecomas, and steroid cell tumors maintain stable demand, with potential for future advancements as molecular features are clarified.

By Product Type: Treatment Dominates Revenue as Molecular Diagnostics Redefine the Front End

Treatment represented 56.77% of the United States sex cord gonadal stromal tumor market in 2025, while diagnostics are expected to grow at a 9.45% CAGR from 2026 to 2031. Surgery, chemotherapy, hormonal therapy, and targeted regimens continue to define the treatment pathway, with surgery playing a critical role in staging and systemic therapy decisions. Targeted and hormonal therapies are driving growth in recurrent disease management. Diagnostics are strengthening as FOXL2 and DICER1 sequencing becomes routine, supported by validated testing from institutions like UCSF Health and Mayo Clinic Laboratories. Multi-marker profiling and advancements in antibody drug conjugate target expression are reshaping the diagnostic landscape, creating a more balanced revenue model between diagnostics and treatment.

By End User: Specialty Centers Drive Standards of Care as Hospitals Anchor Volume

Hospitals captured 55.78% of revenue in 2025, leading the United States sex cord gonadal stromal tumor market due to their role in surgeries, inpatient care, and initial diagnostics. Specialty cancer centers are projected to grow at an 11.33% CAGR through 2031, driven by their expertise in rare tumor management, molecular reviews, and clinical trial access. Institutions like Mount Sinai Health System are expanding referral capacity for complex cases. Academic and research centers are playing a larger role by advancing molecular profiling, biobanking, and translational models, while diagnostic labs benefit from increased use of FOXL2 assays and tumor marker monitoring. Ambulatory surgical centers are gaining share in fertility-preserving procedures, but hospitals and specialty centers remain central for advanced-stage care and research activities.

Geography Analysis

The United States sex cord gonadal stromal tumor (SCGST) market is the most advanced globally due to its concentration of specialist centers, molecular testing infrastructure, and rare-disease oncology funding. The country supports structured care pathways for rare gynecologic tumors through academic referral networks, biomarker testing, and investigator-led trial programs. The Northeast remains the key regional cluster, with cities like Boston and New York attracting complex referrals due to their specialist pathology, clinical trial access, and multidisciplinary treatment teams.

A clear divide exists between large metropolitan systems and regions relying on community-level care in the United States SCGST market. In non-academic hubs, delays occur when ovarian masses are reviewed without specialist pathology or molecular confirmation, slowing entry into specialty treatment channels. Hub-and-spoke care models are addressing this gap, as larger centers extend consultation and referral support to community settings. Mount Sinai’s 2024 expansion highlights this deliberate organization of rare gynecologic oncology capacity.

The South and West are becoming increasingly significant in the United States SCGST market as population growth and specialty care capacity expand beyond the Northeast. On the West Coast, UCSF stands out with its FOXL2 mutation testing and clinical genetics support, enabling faster and accurate molecular confirmations. The Southeast is also gaining relevance as referral networks strengthen around major oncology centers and trial-capable institutions. Over the forecast period, broader testing access and improved referral routing are expected to increase patient participation across the United States SCGST market.